BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Universal Antivirals Could be the Future for Preventing Pandemics

  Since the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks. Now some companies are in the testing phase for just that.

  May 13, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Drug Development

  Study: Inflammatory Proteins From COVID-19 May Cause Long COIVD

  New research from the Allen Institute for Immunology in Seattle has identified inflammatory proteins as a potential driver of the long COVID.

  May 13, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Biotech Bay

  Elon Musk’s Neuralink Beaten to the Clinic by Synchron

  Elon Musk’s Neuralink has been beaten to the clinic by rival brain-computer interface company Synchron which is assessing its implant in individuals with severe paralysis.

  May 13, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Eli Lilly Deals Another Blow to Diabetes with Latest FDA Approval

  In addition to lowering of blood sugar, Mounjaro also enabled patients to lower their weight by 15 to 23 pounds. The drug compared well to other diabetes medications including Novo Nordisk’s semaglutide.

  May 13, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Marinus on Track to Capitalize on Recent Seizure Drug Approval

  Marinus shared positive news in its financial report for the first quarter, led by updates from its Phase III trial on a drug for RSE and research efforts for rare diseases.

  May 13, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Biotech Bay

  BridgeBio Augments Comeback Week with Sale of Priority Review Voucher

  BridgeBio said it would sell the voucher for $110 million but did not disclose the identity of the company planning to acquire the voucher.

  May 13, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  UCB Psoriasis Drug Will Need to Wait for US Approval

  The rejection appears to be related to pre-approval inspection issues that need to be resolved before it can be approved.

  May 13, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Pharm Country

  Yale Researchers are Quantifying Genetic and Environmental Factors in Cancer

  Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.

  May 13, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More

  Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio’s pediatric methylmalonic acidemia study is back up and running and another look at Roche’s TIGIT flop.

  May 13, 2022

   · 

  7 min read

   · 

  Mark Terry
• 

  MIT Study: Brain Circuit in Anterior Thalamus is Critical for Memory

  A study by researchers at the Massachusetts Institute of Technolog (MIT) have found a brain circuit in the anterior thalamus that is critical for memory function.

  May 13, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.